KR101512386B1 - 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 - Google Patents

미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 Download PDF

Info

Publication number
KR101512386B1
KR101512386B1 KR1020080032673A KR20080032673A KR101512386B1 KR 101512386 B1 KR101512386 B1 KR 101512386B1 KR 1020080032673 A KR1020080032673 A KR 1020080032673A KR 20080032673 A KR20080032673 A KR 20080032673A KR 101512386 B1 KR101512386 B1 KR 101512386B1
Authority
KR
South Korea
Prior art keywords
metformin
mitiglinide
layer
pharmaceutically acceptable
preparation
Prior art date
Application number
KR1020080032673A
Other languages
English (en)
Korean (ko)
Other versions
KR20090107262A (ko
Inventor
한진우
이석
김영훈
Original Assignee
제이더블유중외제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이더블유중외제약 주식회사 filed Critical 제이더블유중외제약 주식회사
Priority to KR1020080032673A priority Critical patent/KR101512386B1/ko
Priority to TW098111635A priority patent/TW200946111A/zh
Priority to PCT/KR2009/001809 priority patent/WO2009125975A2/ko
Priority to JP2011503905A priority patent/JP2011516544A/ja
Priority to CN2009801124437A priority patent/CN101990427A/zh
Publication of KR20090107262A publication Critical patent/KR20090107262A/ko
Application granted granted Critical
Publication of KR101512386B1 publication Critical patent/KR101512386B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020080032673A 2008-04-08 2008-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 KR101512386B1 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020080032673A KR101512386B1 (ko) 2008-04-08 2008-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
TW098111635A TW200946111A (en) 2008-04-08 2009-04-08 Complex formulation comprising metformin and mitiglinide, and method for preparation thereof
PCT/KR2009/001809 WO2009125975A2 (ko) 2008-04-08 2009-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
JP2011503905A JP2011516544A (ja) 2008-04-08 2009-04-08 ミチグリニドおよびメトホルミンの複合製剤並びにその製造方法
CN2009801124437A CN101990427A (zh) 2008-04-08 2009-04-08 米格列奈及二甲双胍的复合制剂及其制造方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080032673A KR101512386B1 (ko) 2008-04-08 2008-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020150040676A Division KR101591357B1 (ko) 2015-03-24 2015-03-24 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법

Publications (2)

Publication Number Publication Date
KR20090107262A KR20090107262A (ko) 2009-10-13
KR101512386B1 true KR101512386B1 (ko) 2015-04-17

Family

ID=41162388

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020080032673A KR101512386B1 (ko) 2008-04-08 2008-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법

Country Status (5)

Country Link
JP (1) JP2011516544A (sl)
KR (1) KR101512386B1 (sl)
CN (1) CN101990427A (sl)
TW (1) TW200946111A (sl)
WO (1) WO2009125975A2 (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CA2780939C (en) * 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Bilayer tablet formulations
CN108354930A (zh) 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
TWI541030B (zh) * 2010-07-06 2016-07-11 健生藥品公司 用於糖尿病協同治療之調配物
KR101441355B1 (ko) * 2013-05-29 2014-09-17 주식회사 다림바이오텍 레파글리니드 및 메트포르민을 함유하는 이층정 및 그의 제조방법
CN110840855B (zh) * 2019-11-27 2022-04-12 哈尔滨珍宝制药有限公司 依托考昔片及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043853A1 (es) * 2005-10-12 2007-04-19 World-Trade Import-Export, Wtie, Ag. Composiciones farmacéuticas que comprenden sustan- cias antidiabéticas combinadas para su uso en diabete mellitus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE334718T1 (de) * 2000-10-30 2006-08-15 Ortho Mcneil Pharm Inc Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
KR100705210B1 (ko) * 2004-09-23 2007-04-06 주식회사 한독약품 경구투여를 위한 당뇨병 치료용 약제학적 복합제제
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043853A1 (es) * 2005-10-12 2007-04-19 World-Trade Import-Export, Wtie, Ag. Composiciones farmacéuticas que comprenden sustan- cias antidiabéticas combinadas para su uso en diabete mellitus

Also Published As

Publication number Publication date
KR20090107262A (ko) 2009-10-13
TW200946111A (en) 2009-11-16
JP2011516544A (ja) 2011-05-26
WO2009125975A3 (ko) 2009-12-03
WO2009125975A2 (ko) 2009-10-15
CN101990427A (zh) 2011-03-23

Similar Documents

Publication Publication Date Title
AU2020294268B2 (en) Sustained-release formulations of colchicine and methods of using same
KR100812538B1 (ko) 약물 제어방출형 메트포르민-글리메피리드 복합제제
KR101241624B1 (ko) 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
JP6122098B2 (ja) オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
JP2012530135A (ja) ジペプチジルペプチダーゼ−４阻害剤及びピオグリタゾンの併用医薬組成物
JP2010505943A (ja) 時間治療理論に基づく循環器疾患の治療用組合せ製剤
KR101512386B1 (ko) 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
KR101882946B1 (ko) 모사프리드와 라베프라졸의 복합제제
TWI606848B (zh) 包含格米列汀與美氟明的組合藥物及其製備方法
KR101272470B1 (ko) 레보드로프로피진을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
CA2777231A1 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
KR20140113512A (ko) 약제학적 복합제제
KR20100008356A (ko) 칼슘채널길항제를 포함하는 약제학적 제제
EP4112047A1 (en) Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin
KR101591357B1 (ko) 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
KR101265491B1 (ko) 사포그릴레이트염산염을 함유하는 용출률이 조절된 경구용 다층정제 및 이의 제조방법
JP2009511441A (ja) プラルナカサンの遅延処方物
JP2024524113A (ja) シタグリプチン、ダパグリフロジン及びメトホルミンを含む経口用複合錠剤
KR20230009020A (ko) 시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제
EP4385501A1 (en) A pharmaceutical formulation comprising linagliptin, pioglitazone and a sglt-2 inhibitor
CN116490178A (zh) Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
A107 Divisional application of patent
AMND Amendment
B701 Decision to grant
FPAY Annual fee payment

Payment date: 20180410

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20190221

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20200312

Year of fee payment: 6